Skip to main content Skip to section navigation Skip to footer
Achieve Life Sciences, Inc. IR Overview
Achieve Life Sciences Logo
  • Home
  • About
  • Products
  • Investors
  • News
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Information
    • Overview
    • Management Team
    • Contacts
  • Financial Information
    • Overview
    • Financial Results
  • Stock Data
    • Quote and Chart
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Corporate Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Whistleblower Information
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Presentations
  • Email Alerts
Sep 4, 2019 5:30 am EDT
Achieve Life Sciences Announces Presentations at Upcoming Investor Conferences
Aug 8, 2019 5:39 pm EDT
/C O R R E C T I O N -- Achieve Life Sciences, Inc./
Aug 8, 2019 4:05 pm EDT
Achieve Reports Financial Results for Second Quarter 2019 and Provides Cytisinicline Clinical Development Update
Jul 30, 2019 5:30 am EDT
Achieve Life Sciences to Announce Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 8, 2019
Jul 23, 2019 5:30 am EDT
Achieve Life Sciences Extends Collaboration with the National Institutes of Health to Advance the Development of Cytisinicline for Smoking Cessation
Jun 21, 2019 5:30 am EDT
Achieve Life Sciences Announces Phase 2b ORCA-1 Trial Data Accepted for Oral Presentation at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference
Jun 11, 2019 7:00 am EDT
Achieve Life Sciences Announces Statistically Significant Improvement in Quit Rates for Simplified Cytisinicline Dosing Schedule in Phase 2b ORCA-1 Dose-Selection Trial
Jun 3, 2019 4:05 pm EDT
Achieve Receives $4.2 Million from Exercise of Warrants
May 30, 2019 5:30 am EDT
Achieve Announces Patent Granted in the U.S. for Novel Formulation of Cytisinicline
May 15, 2019 4:05 pm EDT
Achieve Reports Financial Results for First Quarter 2019 and Provides Cytisinicline Clinical Development Update
  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • Page 20
  • Page 21
  • Page 22
  • Page 23
  • Next Pagearrow_forward
rss_feed News RSS
  • emailEmail Alerts
  • contact_pageContacts
  • rss_feedRSS News Feed
  • account_treeSitemap
  • US Headquarters
  • 22722 29th Dr SE,
    Suite 100
  • Bothell, WA 98021
  • Phone: (425) 686-1500
  • Vancouver Office
  • 1040 W Georgia Street,
    Suite 1030
  • Vancouver, BC V6E 4H1

About

  • About
  • Management Team
  • Board of Directors
  • Scientific Advisors
  • Careers

For Investors

  • Investors
  • News
  • Corporate Governance
  • Financial Information
  • SEC Filings

Recent News

April 21, 2025
Achieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine
More News

© Copyright 2025 | Achieve Life Sciences, Inc. All Rights Reserved

  • Privacy Policy
  • Disclaimer
  • Contact
  • twitter
  • linkedin